Ralph William Charlton III
Known title: Chief Medical OfficerCIK: 0001919397
Associated companies
Transaction History
| SPRB | ▲ Buy | Option Exercise | 26,600 | $0 | 12/16/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 9,491 | $4K | 12/16/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 11,329 | $4K | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 31,750 | $0 | 12/16/2024 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 106,400 | $0 | 12/10/2024 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 37,964 | $20K | 12/10/2024 | View on chart |
| SPRB | ▲ Buy | Grant | 9,361 | $9K | 12/29/2023 | View on chart |
| SPRB | ▲ Buy | Option Exercise | 31,750 | $0 | 12/15/2023 | View on chart |
| SPRB | ▼ Sell | Tax Withholding | 10,980 | $18K | 12/15/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 12,378 | $12K | 6/30/2023 | View on chart |
| SPRB | ▲ Buy | Grant | 12,864 | $12K | 12/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.